Ciprofol Versus Propofol for Sedation in Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis in a Chinese Population.

IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL
Drug Design, Development and Therapy Pub Date : 2025-06-25 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S522678
Hongyu Yang, Ping Lai, Xiaoyu Qin, Yiyang Cui, Xiaojia Zhang, Haiqing Zhang, Yichen Ding, Ersheng Ye, Yaping Wu, Bingxu Ren
{"title":"Ciprofol Versus Propofol for Sedation in Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis in a Chinese Population.","authors":"Hongyu Yang, Ping Lai, Xiaoyu Qin, Yiyang Cui, Xiaojia Zhang, Haiqing Zhang, Yichen Ding, Ersheng Ye, Yaping Wu, Bingxu Ren","doi":"10.2147/DDDT.S522678","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Ciprofol (HSK3486) is a novel intravenous anesthetic structurally similar to propofol; however, its advantages over propofol remain unclear. This study aimed to compare the safety, efficacy, and satisfaction outcomes of ciprofol and propofol during gastrointestinal endoscopy.</p><p><strong>Patients and methods: </strong>This systematic review incorporated all available comparative trials assessing ciprofol versus propofol for endoscopic sedation following a comprehensive search strategy across eight biomedical databases-Web of Science, Embase, PubMed, and Cochrane Library, along with major Chinese repositories (CNKI, Wanfang, CBM, and VIP)-through September 2023. Evidence synthesis was conducted per PRISMA guidelines, with methodological rigor enhanced through prospective trial registry screening and implementation of GRADE framework for evidence grading.</p><p><strong>Results: </strong>This systematic review included 45 randomized controlled trials involving 6884 patients who met predefined methodological and clinical eligibility thresholds. Very low to moderate certainty evidence showed that ciprofol induced sedation or anesthesia comparable to that of propofol (relative risk [RR]: 1.00, 95% confidence interval [CI]: 1.00 to 1.01), with both agents demonstrating similar procedural efficiency. Furthermore, ciprofol was associated with a reduced incidence of complications, including hypotension (RR: 0.60, 95% CI: 0.51 to 0.70), bradycardia (RR: 0.69, 95% CI: 0.56 to 0.85), nausea and vomiting (RR: 0.67, 95% CI: 0.54 to 0.84), hypoxia (RR: 0.38, 95% CI: 0.31 to 0.48), respiratory depression (RR: 0.39, 95% CI: 0.28 to 0.56), apnea (RR: 0.35, 95% CI: 0.23 to 0.53), and injection pain (RR: 0.13, 95% CI: 0.09 to 0.17), while also enhancing patient and anesthesiologist satisfaction.</p><p><strong>Conclusion: </strong>Ciprofol-induced sedation or anesthesia was comparable to propofol, with both drugs demonstrating similar procedural efficiency. However, ciprofol was associated with lower risk of adverse reactions and higher satisfaction among patients and anesthesiologists. Ciprofol may represent a superior sedative option for gastrointestinal endoscopy.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5369-5385"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S522678","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Ciprofol (HSK3486) is a novel intravenous anesthetic structurally similar to propofol; however, its advantages over propofol remain unclear. This study aimed to compare the safety, efficacy, and satisfaction outcomes of ciprofol and propofol during gastrointestinal endoscopy.

Patients and methods: This systematic review incorporated all available comparative trials assessing ciprofol versus propofol for endoscopic sedation following a comprehensive search strategy across eight biomedical databases-Web of Science, Embase, PubMed, and Cochrane Library, along with major Chinese repositories (CNKI, Wanfang, CBM, and VIP)-through September 2023. Evidence synthesis was conducted per PRISMA guidelines, with methodological rigor enhanced through prospective trial registry screening and implementation of GRADE framework for evidence grading.

Results: This systematic review included 45 randomized controlled trials involving 6884 patients who met predefined methodological and clinical eligibility thresholds. Very low to moderate certainty evidence showed that ciprofol induced sedation or anesthesia comparable to that of propofol (relative risk [RR]: 1.00, 95% confidence interval [CI]: 1.00 to 1.01), with both agents demonstrating similar procedural efficiency. Furthermore, ciprofol was associated with a reduced incidence of complications, including hypotension (RR: 0.60, 95% CI: 0.51 to 0.70), bradycardia (RR: 0.69, 95% CI: 0.56 to 0.85), nausea and vomiting (RR: 0.67, 95% CI: 0.54 to 0.84), hypoxia (RR: 0.38, 95% CI: 0.31 to 0.48), respiratory depression (RR: 0.39, 95% CI: 0.28 to 0.56), apnea (RR: 0.35, 95% CI: 0.23 to 0.53), and injection pain (RR: 0.13, 95% CI: 0.09 to 0.17), while also enhancing patient and anesthesiologist satisfaction.

Conclusion: Ciprofol-induced sedation or anesthesia was comparable to propofol, with both drugs demonstrating similar procedural efficiency. However, ciprofol was associated with lower risk of adverse reactions and higher satisfaction among patients and anesthesiologists. Ciprofol may represent a superior sedative option for gastrointestinal endoscopy.

环丙酚与异丙酚在胃肠道内窥镜中的镇静作用:中国人群的系统回顾和荟萃分析。
目的:环丙酚(HSK3486)是一种结构类似异丙酚的新型静脉麻醉剂;然而,它相对于异丙酚的优势尚不清楚。本研究旨在比较环丙酚和异丙酚在胃肠道内窥镜检查中的安全性、有效性和满意度。患者和方法:本系统综述纳入了截至2023年9月8个生物医学数据库(web of Science、Embase、PubMed、Cochrane Library以及主要中文数据库(CNKI、万方、CBM和VIP)的综合检索策略,纳入了评估环丙酚与异丙酚用于内窥镜镇静的所有可用比较试验。根据PRISMA指南进行证据合成,通过前瞻性试验登记筛选和实施GRADE证据分级框架,方法的严谨性得到增强。结果:本系统综述纳入了45项随机对照试验,涉及6884例患者,这些患者符合预定的方法学和临床资格阈值。极低至中等确定性证据表明,环丙酚诱导的镇静或麻醉效果与异丙酚相当(相对危险度[RR]: 1.00, 95%可信区间[CI]: 1.00至1.01),两种药物的程序效率相似。此外,ciprofol与减少相关并发症的发生率,包括低血压(RR: 0.60, 95% CI: 0.51—0.70),心动过缓(RR: 0.69, 95% CI: 0.56—0.85),恶心和呕吐(RR: 0.67, 95% CI: 0.54—0.84),缺氧(RR: 0.38, 95% CI: 0.31—0.48),呼吸抑郁症(RR: 0.39, 95% CI: 0.28—0.56),呼吸暂停(RR: 0.35, 95% CI: 0.23—0.53),和注射疼痛(RR: 0.13, 95% CI: 0.09—0.17),同时提高病人和麻醉师的满意度。结论:环丙酚诱导的镇静或麻醉效果与异丙酚相当,两种药物的程序效率相似。然而,环丙酚的不良反应风险较低,患者和麻醉师的满意度较高。环丙酚可能是胃肠道内窥镜检查的一种优越的镇静选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Design, Development and Therapy
Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY
CiteScore
9.00
自引率
0.00%
发文量
382
审稿时长
>12 weeks
期刊介绍: Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信